A rare immune-mediated fibroinflammatory condition characterized by tumefactive lesions, a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform fibrosis, and often elevated serum IgG4 concentrations. The disease can affect virtually any organ but most commonly involves the pancreas (autoimmune pancreatitis), salivary and lacrimal glands, bile ducts, kidneys, retroperitoneum, and aorta. Left untreated, it leads to progressive fibrosis and organ damage.
Ask a research question about IgG4-Related Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: IgG4-Related Disease
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-05-09T20:30:53Z"
category: Autoimmune
disease_term:
preferred_term: IgG4-related disease
term:
id: MONDO:0017287
label: immunoglobulin G4-related sclerosing disease
parents:
- Autoimmune Disease
- Fibroinflammatory Disease
description: >-
A rare immune-mediated fibroinflammatory condition characterized by
tumefactive lesions, a dense lymphoplasmacytic infiltrate rich in
IgG4-positive plasma cells, storiform fibrosis, and often elevated serum
IgG4 concentrations. The disease can affect virtually any organ but most
commonly involves the pancreas (autoimmune pancreatitis), salivary and
lacrimal glands, bile ducts, kidneys, retroperitoneum, and aorta. Left
untreated, it leads to progressive fibrosis and organ damage.
has_subtypes:
- name: IgG4-Related Autoimmune Pancreatitis (Type 1 AIP)
description: >-
The most common organ manifestation, presenting as diffuse or focal
pancreatic enlargement with characteristic periductal lymphoplasmacytic
infiltrate. Often presents with obstructive jaundice.
- name: IgG4-Related Dacryoadenitis and Sialadenitis
description: >-
Bilateral enlargement of lacrimal and/or salivary glands (historically
called Mikulicz disease). Presents with painless symmetrical gland
swelling.
pathophysiology:
- name: Tfh-Mediated IgG4 Class Switching and Plasma Cell Differentiation
description: >-
Follicular helper T cells provide B-cell help in germinal centers,
promoting plasmablast differentiation and IgG4 class switching that
contributes to the IgG4-positive plasma-cell-rich tissue infiltrate.
cell_types:
- preferred_term: T follicular helper cell
term:
id: CL:0002038
label: T follicular helper cell
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Isotype switching
term:
id: GO:0045190
label: isotype switching
- preferred_term: Plasma cell differentiation
term:
id: GO:0002317
label: plasma cell differentiation
downstream:
- target: IgG4-Positive Plasma Cell Infiltration
description: Tfh-driven class switching and plasmablast differentiation feed the IgG4-positive plasma-cell infiltrate.
evidence:
- reference: DOI:10.3389/fimmu.2024.1413860
reference_title: Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy
supports: SUPPORT
evidence_source: OTHER
snippet: >-
T cell immunity plays a crucial role in the pathogenesis of IgG4-RD,
and follicular helper T cells (Tfh) are particularly important in
germinal center (GC) formation, plasmablast differentiation, and IgG4
class-switching.
explanation: >-
This review supports a distinct Tfh-mediated B-cell help node upstream
of IgG4-positive plasma-cell accumulation.
- name: IgG4-Positive Plasma Cell Infiltration
description: >-
Abundant IgG4-bearing plasma cells infiltrate affected tissues, though
the pathogenic role of IgG4 antibodies themselves remains debated.
cell_types:
- preferred_term: Plasma cell
term:
id: CL:0000786
label: plasma cell
biological_processes:
- preferred_term: Immune response
term:
id: GO:0006955
label: immune response
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
IgG4-related disease (IgG4-RD) has emerged over the last decade as a
unique immune-mediated condition that links multiple fibro-inflammatory
disorders previously regarded as separate entities
explanation: >-
Establishes IgG4-RD as a unified immune-mediated fibroinflammatory
condition.
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The gold-standard for the diagnosis of IgG4-RD, regardless of the
organ(s) involved, is the identification of typical histopathology
features (e.g., lymphoplasmacytic infiltrate, storiform fibrosis,
obliterative phlebitis) in the context of a significant IgG4+ plasma
cell infiltrate
explanation: >-
Confirms lymphoplasmacytic infiltrate with IgG4+ plasma cells as the
histopathological hallmark.
- name: CD4-Positive Cytotoxic T-Lymphocyte Fibrogenic Cytokine Production
description: >-
Clonally expanded CD4-positive cytotoxic T lymphocytes infiltrate IgG4-RD
lesions and produce inflammatory and profibrotic mediators, including
IL-1beta, TGF-beta1, and IFN-gamma in salivary and lacrimal gland disease.
cell_types:
- preferred_term: CD4-positive cytotoxic T lymphocyte
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
biological_processes:
- preferred_term: Cytokine production
term:
id: GO:0001816
label: cytokine production
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
downstream:
- target: Storiform Fibrosis
description: Profibrotic cytokine-secreting CD4+ CTLs provide an immune-cell mechanism for chronic inflammation and fibrosis.
evidence:
- reference: PMID:26971690
reference_title: Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
IgG4-RD is prominently linked to clonally expanded IL-1β- and
TGF-β1-secreting CD4(+) CTLs in both peripheral blood and inflammatory
tissue lesions.
explanation: >-
Human cohort data support clonally expanded IL-1beta- and
TGF-beta1-secreting CD4+ CTLs as a distinct pathogenic effector node.
- reference: PMID:27358392
reference_title: Lesional CD4+ IFN-γ+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A large fraction of CD4+GZMA+ CTLs in SMGs from patients with IgG4-DS
secreted IFN-γ.
explanation: >-
This salivary-gland IgG4-RD study supports IFN-gamma secretion by
lesional CD4+ cytotoxic T cells.
- name: Storiform Fibrosis
description: >-
A characteristic cartwheel or whorled pattern of fibrosis is a
histopathological hallmark. Activated fibroblasts and myofibroblasts
are driven by profibrotic cytokines from CD4+ CTLs, leading to
progressive tissue remodeling and organ dysfunction.
cell_types:
- preferred_term: Fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: Collagen fibril organization
term:
id: GO:0030199
label: collagen fibril organization
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The major histopathologic features include a dense lymphoplasmacytic
infiltrate, fibrosis that has a storiform pattern in focal (or diffuse)
areas, and obliterative phlebitis.
explanation: >-
Storiform fibrosis identified as one of the three major
histopathological features of IgG4-RD.
histopathology:
- name: Dense Lymphoplasmacytic Infiltrate with IgG4-Positive Plasma Cells
diagnostic: true
frequency: VERY_FREQUENT
description: >-
Tissue biopsy shows a dense lymphoplasmacytic infiltrate with increased
IgG4-positive plasma cells or an increased IgG4+/IgG+ plasma-cell ratio.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The pathology diagnosis of IgG4-RD is predicated upon the presence of
both specific histopathologic features and an increased number of IgG4+
plasma cells (or IgG4+/IgG+ ratio) in affected tissue
explanation: >-
This cohort-based pathology description supports IgG4-positive
lymphoplasmacytic infiltration as a defining tissue finding.
- name: Storiform Fibrosis
diagnostic: true
frequency: FREQUENT
description: >-
Fibrosis in a storiform, whorled, or cartwheel pattern is one of the
characteristic microscopic features of IgG4-RD.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The major histopathologic features include a dense lymphoplasmacytic
infiltrate, fibrosis that has a storiform pattern in focal (or diffuse)
areas, and obliterative phlebitis.
explanation: >-
The quoted pathology summary names storiform fibrosis as a major
IgG4-RD histopathologic feature.
- name: Obliterative Phlebitis
diagnostic: true
frequency: FREQUENT
description: >-
Obliterative phlebitis, venous inflammation with luminal obliteration, is
part of the classic IgG4-RD histopathology triad.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The major histopathologic features include a dense lymphoplasmacytic
infiltrate, fibrosis that has a storiform pattern in focal (or diffuse)
areas, and obliterative phlebitis.
explanation: >-
The quoted pathology summary names obliterative phlebitis as a major
IgG4-RD histopathologic feature.
phenotypes:
- category: Gastrointestinal
name: Autoimmune Pancreatitis
frequency: VERY_FREQUENT
diagnostic: true
notes: >-
Type 1 autoimmune pancreatitis is the most common manifestation. Presents
with painless jaundice, diffuse pancreatic enlargement, and elevated
serum IgG4.
phenotype_term:
preferred_term: Pancreatitis
term:
id: HP:0001733
label: Pancreatitis
- category: Ophthalmologic
name: Enlarged Lacrimal Glands
frequency: FREQUENT
phenotype_term:
preferred_term: Enlarged lacrimal glands
term:
id: HP:0007734
label: Enlarged lacrimal glands
- category: Hepatobiliary
name: Sclerosing Cholangitis
frequency: FREQUENT
notes: >-
IgG4-related sclerosing cholangitis can mimic primary sclerosing
cholangitis or cholangiocarcinoma but responds to corticosteroids.
phenotype_term:
preferred_term: Sclerosing cholangitis
term:
id: HP:0030991
label: Sclerosing cholangitis
- category: Hepatobiliary
name: Jaundice
frequency: FREQUENT
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
- category: Abdominal
name: Retroperitoneal Fibrosis
frequency: FREQUENT
phenotype_term:
preferred_term: Retroperitoneal fibrosis
term:
id: HP:0005200
label: Retroperitoneal fibrosis
- category: Renal
name: Renal Insufficiency
frequency: OCCASIONAL
notes: >-
IgG4-related tubulointerstitial nephritis or membranous nephropathy
can lead to progressive renal dysfunction.
phenotype_term:
preferred_term: Renal insufficiency
term:
id: HP:0000083
label: Renal insufficiency
- category: Constitutional
name: Weight Loss
frequency: FREQUENT
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
biochemical:
- name: Serum IgG4
presence: Elevated
context: >-
Elevated serum IgG4 (>135 mg/dL) is found in 51-70% of patients with
active disease, but is neither sensitive nor specific.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Only 51% of the patients with active disease had elevated serum IgG4
concentrations.
explanation: >-
Large cohort study showing that nearly half of active IgG4-RD patients
have normal serum IgG4, demonstrating imperfect sensitivity.
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients with active disease and elevated serum IgG4 concentrations
were older, had a higher IgG4-RD RI score, a greater number of organs
involved, lower complement levels, higher absolute eosinophil counts,
and higher IgE levels
explanation: >-
Elevated serum IgG4 identifies a subset with more severe disease.
- name: Total IgG
presence: Elevated
context: >-
Polyclonal hypergammaglobulinemia is common.
- name: Complement C3 and C4
presence: Decreased
context: >-
Hypocomplementemia may occur, particularly in patients with renal
involvement, suggesting immune complex-mediated damage.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
patients with active disease and elevated serum IgG4 concentrations
were older, had a higher IgG4-RD RI score, a greater number of organs
involved, lower complement levels
explanation: >-
Lower complement levels associated with more severe IgG4-RD phenotype.
treatments:
- name: Glucocorticoids
description: >-
First-line therapy with excellent initial response rates. However,
sustained remission is achieved in only about 23% of patients, with
most relapsing upon steroid discontinuation.
evidence:
- reference: PMID:25988916
reference_title: "IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment with glucocorticoids failed to produce sustained remission
in 77% of patients.
explanation: >-
While glucocorticoids are first-line, they fail to produce sustained
remission in the majority of patients.
- reference: PMID:25809420
reference_title: "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
International Consensus Guidance Statement on the Management and
Treatment of IgG4-Related Disease.
explanation: >-
International consensus guidelines established for IgG4-RD management.
treatment_term:
preferred_term: glucocorticoid therapy
term:
id: NCIT:C122080
label: Systemic Corticosteroid Therapy
- name: Rituximab
description: >-
Anti-CD20 monoclonal antibody used for relapsing or refractory disease.
Effective in inducing remission and reducing serum IgG4 levels by
depleting B cell precursors of IgG4-producing plasma cells.
treatment_term:
preferred_term: rituximab therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
datasets:
references:
- reference: DOI:10.1002/cti2.1477
title: The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin <scp>G4</scp>‐related disease
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Immunoglobulin G4 (IgG4)‐related disease is a chronic fibroinflammatory disease mediated by immune disorders.
supporting_text: Immunoglobulin G4 (IgG4)‐related disease is a chronic fibroinflammatory disease mediated by immune disorders.
evidence:
- reference: DOI:10.1002/cti2.1477
reference_title: The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin <scp>G4</scp>‐related disease
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Immunoglobulin G4 (IgG4)‐related disease is a chronic fibroinflammatory disease mediated by immune disorders.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1016/j.ccm.2019.05.005
title: Immunoglobulin G4–related Disease
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Immunoglobulin G4–related Disease
supporting_text: Immunoglobulin G4–related Disease
- reference: DOI:10.1093/rap/rkae020
title: 'Current and future advances in practice: IgG4-related disease'
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death.
supporting_text: IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death.
evidence:
- reference: DOI:10.1093/rap/rkae020
reference_title: 'Current and future advances in practice: IgG4-related disease'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1111/jgh.15809
title: Nationwide epidemiological survey of immunoglobulin G4‐related disease with malignancy in Japan
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Nationwide epidemiological survey of immunoglobulin G4‐related disease with malignancy in Japan
supporting_text: and AimTo clarify the clinicoepidemiological characteristics of immunoglobulin G4 (IgG4)‐related disease (IgG4‐RD) with malignancy, a nationwide epidemiological survey was conducted.MethodsImmunoglobulin G4‐related disease patients with malignancy who had visited selected hospitals in Japan were surveyed.
evidence:
- reference: DOI:10.1111/jgh.15809
reference_title: Nationwide epidemiological survey of immunoglobulin G4‐related disease with malignancy in Japan
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: and AimTo clarify the clinicoepidemiological characteristics of immunoglobulin G4 (IgG4)‐related disease (IgG4‐RD) with malignancy, a nationwide epidemiological survey was conducted.MethodsImmunoglobulin G4‐related disease patients with malignancy who had visited selected hospitals in Japan were surveyed.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1111/resp.14422
title: Thoracic manifestations of <scp>IgG4</scp>‐related disease
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Immunoglobulin G4‐related disease (IgG4‐RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year.
supporting_text: Immunoglobulin G4‐related disease (IgG4‐RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year.
evidence:
- reference: DOI:10.1111/resp.14422
reference_title: Thoracic manifestations of <scp>IgG4</scp>‐related disease
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Immunoglobulin G4‐related disease (IgG4‐RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1136/annrheumdis-2018-214603
title: 'Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts'
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: 'Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts'
supporting_text: 'Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts'
- reference: DOI:10.1136/annrheumdis-2019-216561
title: The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
supporting_text: The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
- reference: DOI:10.1177/2050640620934911
title: European Guideline on IgG4‐related digestive disease – UEG and SGF evidence‐based recommendations
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: The overall objective of these guidelines is to provide evidence‐based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)‐related digestive disease in adults and children.
supporting_text: The overall objective of these guidelines is to provide evidence‐based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)‐related digestive disease in adults and children.
evidence:
- reference: DOI:10.1177/2050640620934911
reference_title: European Guideline on IgG4‐related digestive disease – UEG and SGF evidence‐based recommendations
supports: SUPPORT
evidence_source: OTHER
snippet: The overall objective of these guidelines is to provide evidence‐based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)‐related digestive disease in adults and children.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1182/hematology.2024000584
title: IgG4-related disease for the hematologist
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Immunoglobulin G4–related disease (IgG4-RD) is an immune-mediated disease with many important manifestations in hematopoietic and lymphoid tissue.
supporting_text: Immunoglobulin G4–related disease (IgG4-RD) is an immune-mediated disease with many important manifestations in hematopoietic and lymphoid tissue.
evidence:
- reference: DOI:10.1182/hematology.2024000584
reference_title: IgG4-related disease for the hematologist
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Immunoglobulin G4–related disease (IgG4-RD) is an immune-mediated disease with many important manifestations in hematopoietic and lymphoid tissue.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.1186/s13023-014-0110-z
title: 'IgG4- related disease: an orphan disease with many faces'
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: 'IgG4- related disease: an orphan disease with many faces'
supporting_text: 'IgG4- related disease: an orphan disease with many faces'
- reference: DOI:10.12775/qs.2024.22.54293
title: 'IgG4-Related Disease: Comprehensive Overview of Pathogenesis, Clinical Manifestations, and Diagnostic Challenges.'
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: IgG4-related disease (IgG4-RD) is a progressive and potentially life-threatening condition characterized by immune system activation and tissue fibrosis, affecting various organs such as the pancreas, kidneys, and lungs.
supporting_text: IgG4-related disease (IgG4-RD) is a progressive and potentially life-threatening condition characterized by immune system activation and tissue fibrosis, affecting various organs such as the pancreas, kidneys, and lungs.
evidence:
- reference: DOI:10.12775/qs.2024.22.54293
reference_title: 'IgG4-Related Disease: Comprehensive Overview of Pathogenesis, Clinical Manifestations, and Diagnostic Challenges.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: IgG4-related disease (IgG4-RD) is a progressive and potentially life-threatening condition characterized by immune system activation and tissue fibrosis, affecting various organs such as the pancreas, kidneys, and lungs.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.3389/fimmu.2024.1272084
title: IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: Immunoglobulins are an essential part of the humoral immune response.
supporting_text: Immunoglobulins are an essential part of the humoral immune response.
evidence:
- reference: DOI:10.3389/fimmu.2024.1272084
reference_title: IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease
supports: SUPPORT
evidence_source: OTHER
snippet: Immunoglobulins are an essential part of the humoral immune response.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
- reference: DOI:10.3389/fimmu.2024.1413860
title: Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy
found_in:
- IgG4-Related_Disease-deep-research-falcon.md
findings:
- statement: IgG4-related disease (IgG4-RD) is a recently described autoimmune disorder characterized by elevated serum IgG4 levels and tissue infiltration of IgG4+ plasma cells in multiple organ systems.
supporting_text: IgG4-related disease (IgG4-RD) is a recently described autoimmune disorder characterized by elevated serum IgG4 levels and tissue infiltration of IgG4+ plasma cells in multiple organ systems.
evidence:
- reference: DOI:10.3389/fimmu.2024.1413860
reference_title: Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy
supports: SUPPORT
evidence_source: OTHER
snippet: IgG4-related disease (IgG4-RD) is a recently described autoimmune disorder characterized by elevated serum IgG4 levels and tissue infiltration of IgG4+ plasma cells in multiple organ systems.
explanation: Deep research cited this publication as relevant literature for IgG4-Related Disease.
IgG4-related disease is a systemic, immune-mediated fibroinflammatory disorder that can produce tumefactive (mass-like) lesions in one or multiple organs and is unified by characteristic histopathology and clinicopathologic correlation (wallace2024currentandfuture pages 2-4, chen2024igg4relateddiseasefor pages 1-2). A core reason IgG4-RD is diagnostically challenging is that no single serologic test is both sensitive and specific, so biopsy and integrative assessment are central (wallace2024currentandfuture pages 2-4, bartoszek2024igg4relateddiseasecomprehensive pages 4-7).
Key diagnostic concept: tissue lesions typically show (i) dense lymphoplasmacytic infiltrate enriched for IgG4+ plasma cells, (ii) storiform fibrosis, and (iii) obliterative phlebitis, often with eosinophilia (chen2024igg4relateddiseasefor pages 1-2, wallace2024currentandfuture pages 2-4).
Direct abstract quote (identifier resource): Pieringer et al. state: “Immunoglobulin G4- related disease (IgG4-RD) is a rare systemic fibro-inflammatory disorder (ORPHA284264).” (pieringer2014igg4relateddisease pages 1-2)
Commonly used alternative phrasings include “IgG4-related disease,” “IgG4-RD,” and organ-specific manifestations (e.g., type 1 autoimmune pancreatitis; IgG4-related sclerosing cholangitis; retroperitoneal fibrosis as a phenotype) (chen2024igg4relateddiseasefor pages 1-2, pieringer2014igg4relateddisease pages 2-4, wallace2024currentandfuture pages 2-4).
The information below is derived primarily from aggregated disease-level resources (peer-reviewed reviews and guidelines) and from human cohort studies/registries and clinical trial registry records (wallace2024currentandfuture pages 2-4, wallace2020the2019american pages 1-1, wallace2024currentandfuture pages 1-2, NCT07148791 chunk 2).
The aetiology remains incompletely resolved, but convergent evidence indicates a B cell–T cell–driven immune disorder with downstream fibroinflammation (wallace2024currentandfuture pages 2-4, hao2023thespectrumof pages 2-4).
No unifying infectious trigger is established in the retrieved evidence; reviews emphasize the absence of a consistent infectious cause (bartoszek2024igg4relateddiseasecomprehensive pages 4-7, wallace2019immunoglobuling4relateddisease. pages 1-2).
No specific protective genetic or environmental factors were identified in the retrieved corpus.
Not clearly established in the retrieved corpus; current data support multifactorial susceptibility with organ-specific exposures and HLA background (bartoszek2024igg4relateddiseasecomprehensive pages 4-7, wallace2019immunoglobuling4relateddisease. pages 1-2).
Contemporary clinical practice recognizes reproducible organ-pattern phenotypes, including: - Pancreato-hepatobiliary (type 1 autoimmune pancreatitis; sclerosing cholangitis) (wallace2024currentandfuture pages 2-4, chen2024igg4relateddiseasefor pages 1-2) - Retroperitoneum/aorta (retroperitoneal fibrosis; aortitis/large-vessel disease) (wallace2024currentandfuture pages 2-4, chen2024igg4relateddiseasefor pages 1-2) - Head-and-neck limited (salivary/lacrimal gland enlargement; orbital adnexal disease) (wallace2024currentandfuture pages 2-4) - Mikulicz/systemic (symmetric lacrimal/salivary enlargement plus systemic involvement; typically very high serum IgG4) (wallace2024currentandfuture pages 2-4)
Multi-organ involvement is common (reported as 60–90% in one review) (bartoszek2024igg4relateddiseasecomprehensive pages 4-7).
Thoracic disease is clinically important and often incidental: - Up to 30% of systemic IgG4-RD patients may have thoracic involvement; thoracic disease is the sole manifestation in ~10% (muller2023thoracicmanifestationsof pages 1-2). - Reported estimates across cohorts are ~15–35% thoracic involvement (muller2023thoracicmanifestationsof pages 2-3).
(These are ontology suggestions for knowledge-base encoding; mapping not directly cited in the retrieved literature.) - Tumefactive lesion / mass effect: HP:0002664 (Neoplasm) (used as proxy for mass-like lesion), HP:0033694 (Organomegaly) depending on organ. - Salivary/lacrimal enlargement: HP:0000217 (Xerostomia), HP:0001097 (Dry eyes), HP:0000175 (Parotid enlargement). - Obstructive jaundice (pancreatobiliary): HP:0000952 (Jaundice). - Retroperitoneal fibrosis-related obstruction: HP:0000795 (Ureteral obstruction). - Eosinophilia: HP:0001880 (Eosinophilia). - Hypergammaglobulinemia: HP:0012204 (Hypergammaglobulinemia).
IgG4-RD is not established as a monogenic disorder in the retrieved evidence. Genetic findings are primarily susceptibility associations (HLA and selected non-HLA loci) rather than causal variants (bartoszek2024igg4relateddiseasecomprehensive pages 4-7, motta2024igg4autoantibodiesand pages 15-15).
No recurrent pathogenic germline variants defining IgG4-RD were identified in the retrieved corpus.
Multiple candidate autoantigens have been reported in IgG4-RD. Examples include galectin-3 (reported in 28% of a cohort) and laminin-511 (detected in 50% of subjects with IgG4-related pancreatitis), supporting antigen-driven immunity in at least some patients (wallace2019immunoglobuling4relateddisease. pages 1-2).
Environmental associations appear phenotype-specific: - Occupational exposure to solvents/oils/industrial & metal dusts has been associated with IgG4-related cholangitis/pancreatitis (bartoszek2024igg4relateddiseasecomprehensive pages 4-7). - Smoking and asbestos exposure have been linked to retroperitoneal fibrosis risk (bartoszek2024igg4relateddiseasecomprehensive pages 4-7, wallace2019immunoglobuling4relateddisease. pages 1-2).
No consistent infectious agent trigger is supported in the retrieved evidence (bartoszek2024igg4relateddiseasecomprehensive pages 4-7, wallace2019immunoglobuling4relateddisease. pages 1-2).
Evidence converges on immune dysregulation involving: - B-lineage cells, especially plasmablasts (suggest CL:0000946 plasma cell; plasmablasts are a transitional phenotype). - T follicular helper (Tfh) cells (suggest CL:0000907 T follicular helper cell). - CD4+ cytotoxic T lymphocytes (CD4+ CTLs) (suggest CL:0000899 CD4-positive, alpha-beta T cell; “cytotoxic CD4” is a functional state).
Circulating plasmablasts are an important mechanistic and biomarker node: plasmablast levels correlate with serum IgG4, inflammatory markers, number of involved organs, and disease activity, and they fall with effective therapy and rise with relapse (hao2023thespectrumof pages 2-4, hao2023thespectrumof pages 4-6). A mechanistic link to fibrosis is proposed through plasmablast profibrotic programs (e.g., LOXL2 expression and PDGF-B secretion) (hao2023thespectrumof pages 2-4).
Tfh cells provide B-cell help and promote IgG4 class-switching via IL-4/IL-21 and co-stimulatory interactions. Circulating PD-1+ Tfh measures correlate with serum IgG/IgG4 metrics and the number of organs involved (xu2024pathogenicrolesof pages 2-4). A 2024 review explicitly notes that “the expansion of circulating Tfh2 cells and plasmablasts may also serve as novel biomarkers for disease diagnosis and activity monitoring” (xu2024pathogenicrolesof pages 1-2).
CD4+ CTLs infiltrate lesions and can produce profibrotic mediators such as TGF-β, providing a plausible bridge between immune activation and storiform fibrosis (hao2023thespectrumof pages 2-4).
(These are ontology suggestions; not directly asserted as GO annotations in the retrieved papers.) - GO:0006954 inflammatory response - GO:0042113 B cell activation - GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains - GO:0001525 angiogenesis / vascular remodeling (for obliterative phlebitis context) - GO:0042060 wound healing and GO:0006959 humoral immune response - GO:0045429 positive regulation of nitric oxide biosynthetic process (macrophage-related; hypothesis-level)
A plausible chain supported by current evidence is: antigen-driven or dysregulated immune activation → expansion of Tfh (especially Tfh2-like) and plasmablasts → IgG4 class switching and oligoclonal plasmablast expansion → recruitment/activation of profibrotic T-cell and myeloid programs (including CD4+ CTLs) → storiform fibrosis and organ dysfunction (hao2023thespectrumof pages 2-4, xu2024pathogenicrolesof pages 2-4, wallace2024currentandfuture pages 2-4).
IgG4-RD can affect virtually any organ; commonly involved sites include pancreas and hepatobiliary system, salivary/lacrimal glands and orbit, retroperitoneum/aorta, kidney, lung/mediastinum, and lymph nodes (chen2024igg4relateddiseasefor pages 1-2, pieringer2014igg4relateddisease pages 2-4, wallace2024currentandfuture pages 2-4).
IgG4-RD typically affects middle-aged to older adults (median around late 50s–60 in major cohorts) (chen2024igg4relateddiseasefor pages 1-2, muller2023thoracicmanifestationsof pages 2-3).
The disease often follows a relapsing–remitting course; if under-treated, it can cause irreversible fibrotic organ damage (wallace2024currentandfuture pages 2-4, chen2024igg4relateddiseasefor pages 1-2). Proliferative manifestations tend to respond better than chronic fibrotic disease, which may be less reversible (chen2024igg4relateddiseasefor pages 1-2).
A 2024 practice review summarized a US claims-based analysis reporting: - Incidence: 0.78–1.39 per 100,000 person-years (2015–2019) - Point prevalence: 5.3 per 100,000 persons (as of 1 Jan 2019) (wallace2024currentandfuture pages 1-2)
A thoracic-manifestations review summarizes additional estimates, e.g., Japan incidence approximated at ~1 per 100,000 and prevalence ~0.8 per 100,000 (muller2023thoracicmanifestationsof pages 2-3), while also emphasizing heterogeneity.
Hallmark tissue features include dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis, and eosinophilia. A common supportive threshold is an IgG4/IgG ratio >40% in tissue (chen2024igg4relateddiseasefor pages 1-2).
The 2019 ACR/EULAR criteria provide a validated, points-based framework requiring: entry organ involvement, exclusion criteria application, and weighted inclusion domains across clinical/serologic/radiologic/pathologic data, with classification at ≥20 points (wallace2020the2019american pages 1-1). Performance: - Derived/validated in 1,879 subjects (1,086 cases; 793 mimickers) (wallace2020the2019american pages 1-1) - Validation cohort 1: specificity 99.2%, sensitivity 85.5% at threshold 20 (wallace2020the2019american pages 1-1) - Validation cohort 2: specificity 97.8%, sensitivity 82.0% at threshold 20 (wallace2020the2019american pages 1-1)
Thoracic IgG4-RD has heterogeneous CT patterns and can mimic malignancy or vasculitis; cautious diagnosis includes searching for extra-thoracic disease and integrating serum IgG4/plasmablast measures plus pathology (muller2023thoracicmanifestationsof pages 1-2).
Clinical outcomes vary by phenotype: proliferative manifestations generally respond well to immunosuppression, whereas established fibrotic disease may be less reversible (chen2024igg4relateddiseasefor pages 1-2).
A Japanese nationwide survey reported an estimated overall prevalence of malignancy among IgG4-RD cases of ~10.9% (10,900 per 100,000 cases), and malignant lymphoma ~2.0% (1,985 per 100,000). IgG4-related kidney disease had the highest associated malignancy frequency (17.1%) (sumimoto2022nationwideepidemiologicalsurvey pages 1-1). These data are context-specific (survey methodology) and should be interpreted accordingly.
European evidence-based guidance for IgG4-related digestive disease recommends: - Induction: oral glucocorticoids 0.6–0.8 mg/kg/day for 1 month (typical 30–40 mg/day prednisone equivalent) (lohr2020europeanguidelineon pages 17-19, lohr2020europeanguidelineon pages 1-2) - Response assessment: at week 2–4 using clinical/biochemical/morphological markers (lohr2020europeanguidelineon pages 17-19, lohr2020europeanguidelineon pages 1-2) - Taper: e.g., 5 mg every 2 weeks, over 3–6 months (lohr2020europeanguidelineon pages 17-19) - Relapse: common; guideline notes relapse rates 26–70% and high re-induction success with glucocorticoids (>95%) (lohr2020europeanguidelineon pages 19-20)
Note: A placebo-controlled inebilizumab study is referenced in a 2024 table, but the excerpt available here is truncated and does not provide full registry detail (wallace2024currentandfuture pages 7-8).
No established primary prevention strategies are supported by the retrieved evidence.
No evidence for naturally occurring IgG4-RD in non-human species was retrieved in this run.
No standardized animal model systems were retrieved in the accessible corpus. A mouse immunization experiment linked to laminin-511 is mentioned as supporting an antigen-driven mechanism but details were not available in the retrieved text segments (wallace2019immunoglobuling4relateddisease. pages 1-2).
| Category | Item | Summary | Publication | URL | Citation |
|---|---|---|---|---|---|
| Identifier | Orphanet ID | IgG4-related disease is identified as a rare systemic fibro-inflammatory disorder with Orphanet identifier ORPHA284264. | Pieringer et al., 2014 | https://doi.org/10.1186/s13023-014-0110-z | (pieringer2014igg4relateddisease pages 1-2) |
| Defining histopathology | Lymphoplasmacytic infiltrate rich in IgG4+ plasma cells | Hallmark lesion includes a dense lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells; tissue diagnosis is essential. | Chen, 2024 | https://doi.org/10.1182/hematology.2024000584 | (chen2024igg4relateddiseasefor pages 1-2) |
| Defining histopathology | Storiform fibrosis | Storiform fibrosis is a core histopathologic feature and part of the classic triad used in diagnosis/classification. | Chen, 2024 | https://doi.org/10.1182/hematology.2024000584 | (chen2024igg4relateddiseasefor pages 1-2) |
| Defining histopathology | Obliterative phlebitis | Obliterative phlebitis is a characteristic histologic feature supporting IgG4-RD diagnosis. | Chen, 2024 | https://doi.org/10.1182/hematology.2024000584 | (chen2024igg4relateddiseasefor pages 1-2) |
| Supportive finding | Tissue eosinophilia | Tissue eosinophilia is a common supportive feature accompanying the histopathologic triad. | Chen, 2024 | https://doi.org/10.1182/hematology.2024000584 | (chen2024igg4relateddiseasefor pages 1-2) |
| Supportive finding | Serum IgG4 elevation | Many patients have elevated serum IgG4; this correlates with extent of organ involvement and relapse risk, but is not specific enough to diagnose disease alone. | Wallace et al., 2024 | https://doi.org/10.1093/rap/rkae020 | (wallace2024currentandfuture pages 2-4) |
| Supportive finding | Tissue IgG4/IgG ratio | A commonly used supportive tissue threshold is an IgG4:IgG plasma-cell ratio >40%. | Chen, 2024 | https://doi.org/10.1182/hematology.2024000584 | (chen2024igg4relateddiseasefor pages 1-2) |
| Classification criteria | 2019 ACR/EULAR entry and threshold | Classification uses a 3-step process (typical organ involvement, exclusion criteria, weighted inclusion criteria) with a threshold of ≥20 points. | Wallace et al., 2020 | https://doi.org/10.1136/annrheumdis-2019-216561 | (wallace2020the2019american pages 1-1) |
| Classification performance | Cohort size used in development/validation | Criteria were developed/validated using 1,879 subjects total (1,086 cases and 793 mimickers). | Wallace et al., 2020 | https://doi.org/10.1136/annrheumdis-2019-216561 | (wallace2020the2019american pages 1-1) |
| Classification performance | Validation cohort 1 | At ≥20 points, specificity was 99.2% (95% CI 97.2–99.8) and sensitivity was 85.5% (95% CI 81.9–88.5). | Wallace et al., 2020 | https://doi.org/10.1136/annrheumdis-2019-216561 | (wallace2020the2019american pages 1-1) |
| Classification performance | Validation cohort 2 | At ≥20 points, specificity was 97.8% (95% CI 93.7–99.2) and sensitivity was 82.0% (95% CI 77.0–86.1). | Wallace et al., 2020 | https://doi.org/10.1136/annrheumdis-2019-216561 | (wallace2020the2019american pages 1-1) |
Table: This table summarizes the core disease identifier, defining pathology, supportive findings, and validated 2019 ACR/EULAR classification performance for IgG4-related disease. It is useful as a compact reference for knowledge-base curation and diagnostic context.
References
(pieringer2014igg4relateddisease pages 1-2): Herwig Pieringer, Ilse Parzer, Adelheid Wöhrer, Petra Reis, Bastian Oppl, and Jochen Zwerina. Igg4- related disease: an orphan disease with many faces. Orphanet Journal of Rare Diseases, 9:110-110, Jul 2014. URL: https://doi.org/10.1186/s13023-014-0110-z, doi:10.1186/s13023-014-0110-z. This article has 142 citations and is from a peer-reviewed journal.
(wallace2024currentandfuture pages 2-4): Zachary S Wallace, Guy Katz, Yasmin G Hernandez-Barco, and Matthew C Baker. Current and future advances in practice: igg4-related disease. Rheumatology Advances in Practice, Apr 2024. URL: https://doi.org/10.1093/rap/rkae020, doi:10.1093/rap/rkae020. This article has 71 citations and is from a peer-reviewed journal.
(chen2024igg4relateddiseasefor pages 1-2): Luke Y. C. Chen. Igg4-related disease for the hematologist. Hematology, 2024:594-603, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000584, doi:10.1182/hematology.2024000584. This article has 15 citations and is from a peer-reviewed journal.
(bartoszek2024igg4relateddiseasecomprehensive pages 4-7): Lidia Bartoszek, Dominika Orłowska, Joanna Olszak, Karolina Zalewa, Wojciech Kapłan, Jakub Starownik, and Bartłomiej Gastoł. Igg4-related disease: comprehensive overview of pathogenesis, clinical manifestations, and diagnostic challenges. Quality in Sport, 22:54293, Sep 2024. URL: https://doi.org/10.12775/qs.2024.22.54293, doi:10.12775/qs.2024.22.54293. This article has 0 citations.
(pieringer2014igg4relateddisease pages 2-4): Herwig Pieringer, Ilse Parzer, Adelheid Wöhrer, Petra Reis, Bastian Oppl, and Jochen Zwerina. Igg4- related disease: an orphan disease with many faces. Orphanet Journal of Rare Diseases, 9:110-110, Jul 2014. URL: https://doi.org/10.1186/s13023-014-0110-z, doi:10.1186/s13023-014-0110-z. This article has 142 citations and is from a peer-reviewed journal.
(wallace2020the2019american pages 1-1): Zachary S Wallace, Ray P Naden, Suresh Chari, Hyon K Choi, Emanuel Della-Torre, Jean-Francois Dicaire, Phillip A Hart, Dai Inoue, Mitsuhiro Kawano, Arezou Khosroshahi, Marco Lanzillotta, Kazuichi Okazaki, Cory A Perugino, Amita Sharma, Takako Saeki, Nicolas Schleinitz, Naoki Takahashi, Hisanori Umehara, Yoh Zen, and John H Stone. The 2019 american college of rheumatology/european league against rheumatism classification criteria for igg4-related disease. Annals of the Rheumatic Diseases, 79:77-87, Jan 2020. URL: https://doi.org/10.1136/annrheumdis-2019-216561, doi:10.1136/annrheumdis-2019-216561. This article has 1362 citations and is from a highest quality peer-reviewed journal.
(wallace2024currentandfuture pages 1-2): Zachary S Wallace, Guy Katz, Yasmin G Hernandez-Barco, and Matthew C Baker. Current and future advances in practice: igg4-related disease. Rheumatology Advances in Practice, Apr 2024. URL: https://doi.org/10.1093/rap/rkae020, doi:10.1093/rap/rkae020. This article has 71 citations and is from a peer-reviewed journal.
(NCT07148791 chunk 2): Jian Zhu. Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease. Chinese PLA General Hospital. 2025. ClinicalTrials.gov Identifier: NCT07148791
(hao2023thespectrumof pages 2-4): Qiyuan Hao, Meng Sun, and Yanying Liu. The spectrum of b cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin g4‐related disease. Clinical & Translational Immunology, Jan 2023. URL: https://doi.org/10.1002/cti2.1477, doi:10.1002/cti2.1477. This article has 7 citations and is from a peer-reviewed journal.
(wallace2019immunoglobuling4relateddisease. pages 1-2): Zachary S. Wallace, Cory Perugino, Mark Matza, Vikram Deshpande, Amita Sharma, and John H. Stone. Immunoglobulin g4-related disease. Clinics in chest medicine, 40 3:583-597, Sep 2019. URL: https://doi.org/10.1016/j.ccm.2019.05.005, doi:10.1016/j.ccm.2019.05.005. This article has 70 citations and is from a peer-reviewed journal.
(motta2024igg4autoantibodiesand pages 15-15): Rodrigo V. Motta and Emma L. Culver. Igg4 autoantibodies and autoantigens in the context of igg4-autoimmune disease and igg4-related disease. Frontiers in Immunology, Feb 2024. URL: https://doi.org/10.3389/fimmu.2024.1272084, doi:10.3389/fimmu.2024.1272084. This article has 30 citations and is from a peer-reviewed journal.
(wallace2019clinicalphenotypesof pages 2-3): Zachary S Wallace, Yuqing Zhang, Cory A Perugino, Ray Naden, Hyon K Choi, and John H Stone. Clinical phenotypes of igg4-related disease: an analysis of two international cross-sectional cohorts. Annals of the Rheumatic Diseases, 78:406-412, Mar 2019. URL: https://doi.org/10.1136/annrheumdis-2018-214603, doi:10.1136/annrheumdis-2018-214603. This article has 422 citations and is from a highest quality peer-reviewed journal.
(sumimoto2022nationwideepidemiologicalsurvey pages 1-1): Kimi Sumimoto, Kazushige Uchida, Tsukasa Ikeura, Kenji Hirano, Motohisa Yamamoto, Hiroki Takahashi, Takayoshi Nishino, Ichiro Mizushima, Mitsuhiro Kawano, Terumi Kamisawa, Takako Saeki, Hiroyuki Maguchi, Tomoyuki Ushijima, Masahiro Shiokawa, Hiroshi Seno, Hiroshi Goto, Seiji Nakamura, and Kazuichi Okazaki. Nationwide epidemiological survey of immunoglobulin g4‐related disease with malignancy in japan. Journal of Gastroenterology and Hepatology, 37:1022-1033, Mar 2022. URL: https://doi.org/10.1111/jgh.15809, doi:10.1111/jgh.15809. This article has 26 citations and is from a peer-reviewed journal.
(muller2023thoracicmanifestationsof pages 1-2): Romain Muller, Mikael Ebbo, Paul Habert, Laurent Daniel, Antoine Briantais, Pascal Chanez, Jean Yves Gaubert, and Nicolas Schleinitz. Thoracic manifestations of igg4‐related disease. Respirology (Carlton, Vic.), 28:120-131, Nov 2023. URL: https://doi.org/10.1111/resp.14422, doi:10.1111/resp.14422. This article has 58 citations.
(muller2023thoracicmanifestationsof pages 2-3): Romain Muller, Mikael Ebbo, Paul Habert, Laurent Daniel, Antoine Briantais, Pascal Chanez, Jean Yves Gaubert, and Nicolas Schleinitz. Thoracic manifestations of igg4‐related disease. Respirology (Carlton, Vic.), 28:120-131, Nov 2023. URL: https://doi.org/10.1111/resp.14422, doi:10.1111/resp.14422. This article has 58 citations.
(hao2023thespectrumof pages 4-6): Qiyuan Hao, Meng Sun, and Yanying Liu. The spectrum of b cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin g4‐related disease. Clinical & Translational Immunology, Jan 2023. URL: https://doi.org/10.1002/cti2.1477, doi:10.1002/cti2.1477. This article has 7 citations and is from a peer-reviewed journal.
(xu2024pathogenicrolesof pages 2-4): Jingyi Xu, Jiayu Zhai, and Jinxia Zhao. Pathogenic roles of follicular helper t cells in igg4-related disease and implications for potential therapy. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1413860, doi:10.3389/fimmu.2024.1413860. This article has 18 citations and is from a peer-reviewed journal.
(xu2024pathogenicrolesof pages 1-2): Jingyi Xu, Jiayu Zhai, and Jinxia Zhao. Pathogenic roles of follicular helper t cells in igg4-related disease and implications for potential therapy. Frontiers in Immunology, Jun 2024. URL: https://doi.org/10.3389/fimmu.2024.1413860, doi:10.3389/fimmu.2024.1413860. This article has 18 citations and is from a peer-reviewed journal.
(lohr2020europeanguidelineon pages 17-19): J‐Matthias Löhr, Ulrich Beuers, Miroslav Vujasinovic, Domenico Alvaro, Jens Brøndum Frøkjær, Frank Buttgereit, Gabriele Capurso, Emma L Culver, Enrique de‐Madaria, Emanuel Della‐Torre, Sönke Detlefsen, Enrique Dominguez‐Muñoz, Piotr Czubkowski, Nils Ewald, Luca Frulloni, Natalya Gubergrits, Deniz Guney Duman, Thilo Hackert, Julio Iglesias‐Garcia, Nikolaos Kartalis, Andrea Laghi, Frank Lammert, Fredrik Lindgren, Alexey Okhlobystin, Grzegorz Oracz, Andrea Parniczky, Raffaella Maria Pozzi Mucelli, Vinciane Rebours, Jonas Rosendahl, Nicolas Schleinitz, Alexander Schneider, Eric FH van Bommel, Caroline Sophie Verbeke, Marie Pierre Vullierme, and Heiko Witt. European guideline on igg4‐related digestive disease – ueg and sgf evidence‐based recommendations. United European Gastroenterology Journal, 8:637-666, Jul 2020. URL: https://doi.org/10.1177/2050640620934911, doi:10.1177/2050640620934911. This article has 272 citations and is from a peer-reviewed journal.
(lohr2020europeanguidelineon pages 1-2): J‐Matthias Löhr, Ulrich Beuers, Miroslav Vujasinovic, Domenico Alvaro, Jens Brøndum Frøkjær, Frank Buttgereit, Gabriele Capurso, Emma L Culver, Enrique de‐Madaria, Emanuel Della‐Torre, Sönke Detlefsen, Enrique Dominguez‐Muñoz, Piotr Czubkowski, Nils Ewald, Luca Frulloni, Natalya Gubergrits, Deniz Guney Duman, Thilo Hackert, Julio Iglesias‐Garcia, Nikolaos Kartalis, Andrea Laghi, Frank Lammert, Fredrik Lindgren, Alexey Okhlobystin, Grzegorz Oracz, Andrea Parniczky, Raffaella Maria Pozzi Mucelli, Vinciane Rebours, Jonas Rosendahl, Nicolas Schleinitz, Alexander Schneider, Eric FH van Bommel, Caroline Sophie Verbeke, Marie Pierre Vullierme, and Heiko Witt. European guideline on igg4‐related digestive disease – ueg and sgf evidence‐based recommendations. United European Gastroenterology Journal, 8:637-666, Jul 2020. URL: https://doi.org/10.1177/2050640620934911, doi:10.1177/2050640620934911. This article has 272 citations and is from a peer-reviewed journal.
(lohr2020europeanguidelineon pages 19-20): J‐Matthias Löhr, Ulrich Beuers, Miroslav Vujasinovic, Domenico Alvaro, Jens Brøndum Frøkjær, Frank Buttgereit, Gabriele Capurso, Emma L Culver, Enrique de‐Madaria, Emanuel Della‐Torre, Sönke Detlefsen, Enrique Dominguez‐Muñoz, Piotr Czubkowski, Nils Ewald, Luca Frulloni, Natalya Gubergrits, Deniz Guney Duman, Thilo Hackert, Julio Iglesias‐Garcia, Nikolaos Kartalis, Andrea Laghi, Frank Lammert, Fredrik Lindgren, Alexey Okhlobystin, Grzegorz Oracz, Andrea Parniczky, Raffaella Maria Pozzi Mucelli, Vinciane Rebours, Jonas Rosendahl, Nicolas Schleinitz, Alexander Schneider, Eric FH van Bommel, Caroline Sophie Verbeke, Marie Pierre Vullierme, and Heiko Witt. European guideline on igg4‐related digestive disease – ueg and sgf evidence‐based recommendations. United European Gastroenterology Journal, 8:637-666, Jul 2020. URL: https://doi.org/10.1177/2050640620934911, doi:10.1177/2050640620934911. This article has 272 citations and is from a peer-reviewed journal.
(NCT01584388 chunk 2): John H. Stone, MD. Rituximab in IgG4-RD: A Phase 1-2 Trial. Massachusetts General Hospital. 2012. ClinicalTrials.gov Identifier: NCT01584388
(wallace2024currentandfuture pages 7-8): Zachary S Wallace, Guy Katz, Yasmin G Hernandez-Barco, and Matthew C Baker. Current and future advances in practice: igg4-related disease. Rheumatology Advances in Practice, Apr 2024. URL: https://doi.org/10.1093/rap/rkae020, doi:10.1093/rap/rkae020. This article has 71 citations and is from a peer-reviewed journal.
(NCT03669861 chunk 2): Stone, John H, M.D., M.P.H. Safety and Efficacy of Abatacept in IgG4-Related Disease. Massachusetts General Hospital. 2018. ClinicalTrials.gov Identifier: NCT03669861